You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring
|
|---|---|
| Published in |
BMC Cancer, May 2021
|
| DOI | 10.1186/s12885-021-08184-x |
| Pubmed ID | |
| Authors |
Yoo Young Dominique Lee, Doan Trang Nguyen, Trevor Moodie, Ricky O’Brien, Anne McMaster, Andrew Hickey, Nicole Pritchard, Per Poulsen, Elizaveta Mitkina Tabaksblat, Britta Weber, Esben Worm, David Pryor, Julie Chu, Nicholas Hardcastle, Jeremy Booth, Val Gebski, Tim Wang, Paul Keall |
| Abstract |
Stereotactic Ablative Body Radiotherapy (SABR) is a non-invasive treatment which allows delivery of an ablative radiation dose with high accuracy and precision. SABR is an established treatment for both primary and secondary liver malignancies, and technological advances have improved its efficacy and safety. Respiratory motion management to reduce tumour motion and image guidance to achieve targeting accuracy are crucial elements of liver SABR. This phase II multi-institutional TROG 17.03 study, Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring (LARK), aims to investigate and assess the dosimetric impact of the KIM real-time image guidance technology. KIM utilises standard linear accelerator equipment and therefore has the potential to be a widely available real-time image guidance technology for liver SABR. Forty-six patients with either hepatocellular carcinoma or oligometastatic disease to the liver suitable for and treated with SABR using Kilovoltage Intrafraction Monitoring (KIM) guidance will be included in the study. The dosimetric impact will be assessed by quantifying accumulated patient dose distribution with or without the KIM intervention. The patient treatment outcomes of local control, toxicity and quality of life will be measured. Liver SABR is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of KIM as a potential solution for real-time image guidance in liver SABR. This trial was registered on December 7th 2016 on ClinicalTrials.gov under the trial-ID NCT02984566 . |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 17% |
| Student > Master | 2 | 11% |
| Student > Doctoral Student | 2 | 11% |
| Student > Bachelor | 1 | 6% |
| Lecturer | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 8 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Physics and Astronomy | 4 | 22% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Psychology | 1 | 6% |
| Sports and Recreations | 1 | 6% |
| Social Sciences | 1 | 6% |
| Other | 2 | 11% |
| Unknown | 8 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2022.
All research outputs
#15,292,190
of 23,500,709 outputs
Outputs from BMC Cancer
#3,780
of 8,493 outputs
Outputs of similar age
#245,235
of 439,781 outputs
Outputs of similar age from BMC Cancer
#111
of 310 outputs
Altmetric has tracked 23,500,709 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,493 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,781 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 310 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.